Olaparib Approved in China for Frontline Maintenance in Ovarian Cancer

December 5, 2019 – China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response (PR) to frontline platinum-based chemotherapy. The approval is based on findings from the phase III SOLO-1 trial, in which the PARP … (leggi tutto)